ClinicalTrials.gg
Active, not recruitingNCT06291220453 Ph1 CLLUpdated Sep 11, 2026

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 1 interventional study of Obinutuzumab and ABBV-453 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by AbbVie. Active, not recruiting at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie — 3 open to participants now, 11 under way, 2 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · AbbVie.

Enrollment
38th of 39
4 · median 71
Started
2025
the only one that year
Phase 1
13 of 51
none open now
Primary completion
2027-07
later than 4 of 10 live
Registered
49th of 51
by date

Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 38th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2025, is one of 13 in phase 1, reaches primary completion later than 4 of the 10 other live ones, and was the 49th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, or all of them as a file.
02

Study summary

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adverse events, pharmacokinetics, and change in disease activity will be assessed.

ABBV-453 is an investigational drug for the treatment of CLL and SLL. Participants will be enrolled with a specific target dose and receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the appropriate target dose is achieved. Approximately 60 adult participants with previously R/R CLL/SLL will be enrolled in the study in approximately 40 sites across the world.

Participants will receive intravenous (IV) obinutuzumab as part of the debulking period, followed by escalating doses of oral ABBV-453 until the appropriate target dose is achieved. The estimated study duration is 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic Lymphocytic Leukemia: Small Lymphocytic Lymphoma
  • SLL
  • CLL
  • ABBV-453
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (R/R) chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that has received at least 2 prior systemic therapies and have no available (or established) therapies known to provide clinical benefit and to which the participant would consent to receiving.
  • Laboratory values meeting those listed in the protocol.

Exclusion criteria

Exclusion Criteria:

  • corrected for heart rate (QTc) using Fridericia's correction of > 470 msec (females) or > 450 msec (males), Grade 3 arrythmia, and/or other cardiac abnormalities.
  • Known to be B-cell leukemia/lymphoma 2 inhibitor (BCL-2i) or has received a BCL-2i-containing regimen within (6 months) of starting study drug (e.g., venetoclax, lisaftoclax, BGV-11417).
  • Has active (HIV) infection. HIV testing is not required unless required locally.
  • Recent history (within 6 months) of:

    • Congestive heart failure (defined as , Class 2 or higher).
    • Ischemic cardiovascular event.
    • Cardiac arrhythmia requiring pharmacological or surgical intervention.
    • Pericardial effusion.
    • Pericarditis.
  • Consumes known moderate or strong inhibitors of cytochrome P450 3A isoform subfamily () within 14 day or 5 half-lives of the drug (whichever is shorter) before the first dose of ABBV-453.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1.1 ABBV-453 Dose A

    Participants will receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the dose A is achieved, during the 5 year study duration.

    Drug: Obinutuzumab · Drug: ABBV-453

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to 3 Years

  2. Maximum Administered Dose (MAD) of ABBV-453

    MAD is defined as the highest administered dose if no maximum tolerated dose (MTD) is determined.

    Time frame: Up to 18 Months

  3. Maximum Tolerated Dose (MTD) of ABBV-453

    MTD is defined as the highest dose administered that does not result in a final determination of de-escalate at that dose level.

    Time frame: Up to 18 Months

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ABBV-453

    Cmax is defined as the maximum observed plasma/serum concentration of ABBV-453.

    Time frame: Up to 30 Months

  2. Time to Maximum Observed Concentration (Tmax) of ABBV-453

    Tmax is defined as the time to maximum observed concentration of ABBV-453.

    Time frame: Up to 30 Months

  3. Area Under the Plasma/Serum Concentration Versus Time Curve (AUC) of ABBV-453

    Area under the plasma/serum concentration versus time curve (AUC) of ABBV-453.

    Time frame: Up to 30 Months

  4. Overall Response Rate (ORR)

    Percentage of participants achieving a complete response (CR), complete response with incomplete count recovery (CRi), partial response (PR), or nodular partial response (nPR) using disease-specific criteria per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL, 2018).

    Time frame: Up to 3 Years

  5. Duration of Response (DOR) for Participants with PR/nPR or Better

    DOR is defined as the time between the initial PR or better response assessment per Investigator according to iwCLL criteria to the time of progressive disease (PD) or death of any cause, whichever occurs earlier.

    Time frame: Up to 3 Years

  6. Complete response rate (CRR)

    CRR is defined as the percentage of participants with a best overall response (BOR) of CR or CRi per Investigator review according to iwCLL for participants with relapsed or refractory CLL/SLL, regardless of reasons for study drug discontinuation, and prior to start of subsequent anti-cancer therapies in the participants receiving at least one dose of ABBV-453 monotherapy.

    Time frame: Up to 3 Years

  7. Duration of Complete Response (DOCR)

    DOCR is defined as the time between the initial CR/CRi response assessment per Investigator according to iwCLL criteria to the time of PD or death of any cause, whichever occurs earlier.

    Time frame: Up to 3 Years

  8. Percentage of Participants Achieving an Minimal Residual Disease (MRD) Negativity Among Participants Achieving a PR, nPR, CR, or CRi

    MRD response is defined as \< 1 cell in 10,000 leukocytes (\< 10\^-4).

    Time frame: Up to 3 Years

  9. Progression-free survival (PFS)

    PFS is defined as time from first study treatment to a documented PD (based on iwCLL criteria) as determined by the Investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to 3 Years

  10. Overall survival (OS)

    OS is defined as the time from the first date of study treatment until date of death due to any cause.

    Time frame: Up to 3 Years

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jul 2027, 30 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 30 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 4, 2024
StartActual
Jan 27, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06291220
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Jan 27, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surzetoclax

Start the discussion